Eric Topol’s Deposition Testimony Allowed At First Federal Vioxx Trial

Judge Fallon Ruling: Jury Will Hear And See Dr. Topol Criticize Merck In Video Deposition At Irvin / Plunkett Trial

On November 30, 2005 The Wall Street Journal (WSJ) reported that the jury in the first federal Vioxx trial will hear testimony from Eric Topol, M.D., a leading cardiologist, which apparently is critical of actions Merck took concerning Vioxx.  Dr. Topol had not testified in either of the first two Vioxx trials, Ernst (TX) and Humeston (NJ).

On the first day of the Irvin / Plunkett v. Merck trial, U.S. District Court Judge Eldon Fallon ruled that a videotaped deposition of Dr. Topol can be presented to the jury by lawyers for plaintiff Evelyn Irvin Plunkett, the widow of Richard "Dicky" Irvin.

This testimony was given last week by Eric Topol, chairman of cardiovascular medicine at the Cleveland Clinic, after Dr. Topol was subpoenaed to appear for a deposition by a plaintiff’s lawyer.  Reportedly, Dr. Topol’s deposition testimony had not been presented to the Irvin / Plunkett jury when the November 30 WSJ article was published.  Further, the Topol deposition is "sealed" by order of Judge Fallon, who is presiding over the Irvin / Plunkett trial.

The Wall Street Journal, however, had obtained and reviewed the transcript of this November 2005 Topol deposition.  The November 30 WSJ article reported that Dr. Topol criticized actions Merck took concerning Vioxx in several regards.  Dr. Topol provided testimony which, according to the WSJ article: "accused Merck of scientific misconduct, misrepresenting facts and endangering patients, and said Merck’s former chief executive complained to a top Cleveland Clinic official about Dr. Topol’s activities".

As background, Dr. Topol was one of the earliest critics of Vioxx.  About three years before Merck pulled Vioxx from the market in September 2004, Dr. Topol published a paper in the Journal of the American Medical Association ("JAMA") that raised the issue of whether Vioxx potentially caused heart problems. In his JAMA paper, Dr. Topol said Merck should do a long-term study to investigate whether Vioxx increased cardiovascular risks.

In this recent Topol deposition testimony, according to the WSJ article, Dr. Topol took issue with several crucial points of Merck’s defense in the Vioxx litigation.  For example, in 2000, after the VIGOR study showed that Vioxx was four to five times more likely to cause cardiovascular problems than naproxen (an older painkiller), Merck tried to explain-away this finding with their contention that naproxen somehow provided protection against cardiovascular problems. At this Topol deposition last week, however, Dr. Topol seemingly disagreed with Merck’s explanation when he testified, "There are no data that I am aware of" showing naproxen protects the heart."

Another aspect of Dr. Topol’s deposition in November 2005 had to do with allegations that Merck tried to intimidate him and other doctors who were critical of Merck as regards their marketing of Vioxx.  For this testimony by Dr. Topol we turn to the November 30 WSJ article by Heather Won Tesoriero:

"During his deposition testimony, Dr. Topol said that a colleague at the Cleveland Clinic, Richard Rudick, the director of clinical research, told him that Raymond Gilmartin, the former chief executive and chairman of Merck, called a Cleveland Clinic board of trustee member to complain about Dr. Topol. The call came in mid-October 2004, two weeks after Merck withdrew Vioxx from the market and after Dr. Topol published harsh criticisms of Merck over Vioxx in the New York Times and the New England Journal of Medicine."

"Dr. Topol said that according to Dr. Rudick, Mr. Gilmartin called Malachi Mixon, chairman of the board of trustees at the Cleveland Clinic, and ‘said to Mr. Mixon, what has Merck ever done to the Cleveland Clinic to warrant this?’ In the deposition testimony, Dr. Topol said he never asked Mr. Mixon about the event."

At the time of the November 30 article, Dr. Topol was said to have refused a WSJ reporter’s request for comment about his Vioxx testimony.  Dr. Topol cited the fact that his Vioxx deposition transcript is sealed by order of Judge Fallon.

(Posted by: Tom Lamb)

One response to “Eric Topol’s Deposition Testimony Allowed At First Federal Vioxx Trial”

  1. Mark Summer Avatar
    Mark Summer

    http://www.nytimes.com/2005/12/10/business/10vioxx.html
    * Less than a week after his videotaped lambasting of Merck was
    played in a Houston federal courthouse, Dr. Eric Topol, a prominent
    cardiologist, has lost his title as chief academic officer of the
    Cleveland Clinic’s medical college.
    * Dr. Topol said yesterday that he believed that his demotion might
    be related to his testimony in that case, the third Vioxx lawsuit to
    reach trial. Dr. Topol has questioned Vioxx’s safety for years and
    said in his testimony, played in court last Saturday, that he
    believed that Merck acted irresponsibly and committed scientific
    misconduct when it promoted Vioxx.
    * “The hardest thing in the world is just trying to tell the truth,
    to do the right thing for patients, and you get vilified,” he said
    yesterday. “No wonder nobody stands up to the industry.”
    * Eileen Sheil, a spokeswoman for the clinic, said that Dr. Topol
    was not being punished for his Vioxx testimony. Dr. Topol lost his
    title as part of a broader administrative reorganization, Ms. Sheil
    said. “The organization made the decision that that position was no
    longer needed,” she said.
    Doctor Links Merck Trial to His Demotion
    By ALEX BERENSON
    Published: December 10, 2005
    Less than a week after his videotaped lambasting of Merck was played
    in a Houston federal courthouse, Dr. Eric Topol, a prominent
    cardiologist, has lost his title as chief academic officer of the
    Cleveland Clinic’s medical college.
    In the courthouse yesterday, jurors continued deliberating whether
    Merck’s painkiller Vioxx had caused the death of a Florida main in 2001.
    Dr. Topol said yesterday that he believed that his demotion might be
    related to his testimony in that case, the third Vioxx lawsuit to
    reach trial. Dr. Topol has questioned Vioxx’s safety for years and
    said in his testimony, played in court last Saturday, that he
    believed that Merck acted irresponsibly and committed scientific
    misconduct when it promoted Vioxx.
    “The hardest thing in the world is just trying to tell the truth, to
    do the right thing for patients, and you get vilified,” he said
    yesterday. “No wonder nobody stands up to the industry.”
    Dr. Topol will remain the chief of cardiology at the clinic, a
    prestigious nonprofit health system with almost $4 billion in annual
    revenue, and the loss of his title as chief academic officer does not
    affect his salary. But he will lose his position on the clinic’s
    governing board. His job change was first reported yesterday by The
    Cleveland Plain Dealer.
    Dr. Topol did not offer specific evidence to back his allegation.
    Eileen Sheil, a spokeswoman for the clinic, said that Dr. Topol was
    not being punished for his Vioxx testimony. Dr. Topol lost his title
    as part of a broader administrative reorganization, Ms. Sheil said.
    “The organization made the decision that that position was no longer
    needed,” she said.
    The nine members of the Houston jury planned to begin a third day of
    deliberations today. The lawsuit was brought by the family of Richard
    Irvin, who died in 2001 of a heart attack after taking Vioxx for
    about a month. The case is the first Vioxx lawsuit in federal court,
    after trials in state courts in Texas, where Merck lost, and New
    Jersey, where Merck won.
    Yesterday, lawyers for Mr. Irvin’s family asked Judge Eldon E. Fallon
    to declare a mistrial, claiming that Merck improperly withheld
    information from an article that was published in The New England
    Journal of Medicine in November 2000. On Thursday, the journal wrote
    that Merck had undercounted the number of heart attacks suffered by
    patients in a study of Vioxx to play down the drug’s heart risks.
    Judge Fallon did not rule on the motion for a mistrial.
    Merck stopped selling Vioxx, a once-popular painkiller, last year,
    after a study of the drug showed that it increased the risk of heart
    attacks and strokes.

Leave a Reply to Mark Summer Cancel reply

Your email address will not be published. Required fields are marked *